Bromide

Bromide

SCHEMBL3845868

Cc1sc[n+](CC(=O)c2ccc(O)cc2O)c1C.[Br-]

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.54
HSP90AB1 P08238 1/20 0.49
POLB P06746 1/20 0.47
HTT P42858 2/20 0.43
ESR1 P03372 1/20 0.43
SHBG P04278 1/20 0.43
ESR2 Q92731 1/20 0.43
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA7 P43166 3/20 0.42
CA9 Q16790 3/20 0.42
CA14 Q9ULX7 3/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 4/20 0.40
LMNA P02545 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
P4HB P07237 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL3845852 0.89 KMT2A (0.54) KMT2AHSP90AB1POLBHTTCA12
SCHEMBL6535615 0.88 KMT2A (0.52) KMT2AHSP90AB1POLBHTTCA12
Bromide SCHEMBL3850333 0.83 KMT2A (0.57) KMT2APOLBHTTCA12CA1
SCHEMBL6535177 0.82 KMT2A (0.55) KMT2AHTTCA12CA1CA2
Bromide SCHEMBL5004646 0.80 KMT2A (0.76) KMT2APOLBMAPTALDH1A1LMNA
Bromide SCHEMBL3845600 0.80 KMT2A (0.76) KMT2APOLBMAPTALDH1A1LMNA
SCHEMBL3846298 0.80 KMT2A (0.52) KMT2APOLBSHBGCA12CA1
Bromide SCHEMBL5004644 0.79 KMT2A (0.74) KMT2APOLBMAPTALDH1A1LMNA
Bromide SCHEMBL3849441 0.77 KMT2A (0.63) KMT2APOLBCA12CA1CA2
SCHEMBL6535048 0.77 KMT2A (0.59) KMT2APOLBCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2085086-A2 Method for treating congestive heart failure or diabetic nephropathy Synvista Therapeutics, Inc. (US) 2009-08-05 EP disclosed
US-20090124673-A1 Method for treating diabetic nephropathy SYNVISTA THERAPEUTICS , INC. (US) 2009-05-14 US disclosed
US-20090124674-A1 Method for treating congestive heart failure SYNVISTA THERAPEUTICS, INC. (US) 2009-05-14 US disclosed
US-7432254-B2 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. (US) 2008-10-07 US disclosed
EP-1353669-B1 METHOD FOR TREATING GLAUCOMA ALTEON INC (US) 2007-08-15 EP disclosed
US-7166625-B2 Method for treating fibrotic diseases and other indications ALTEON, INC. (US) 2007-01-23 US disclosed
EP-1305024-A4 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON INC (US) 2006-03-22 EP disclosed
EP-1353669-A4 METHOD FOR TREATING GLAUCOMA IB ALTEON INC (US) 2005-10-19 EP disclosed
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE SYNVISTA THERAPEUTICS, INC. 2004-11-25 US disclosed
EP-1353669-A1 METHOD FOR TREATING GLAUCOMA IB Alteon, Inc. (US) 2003-10-22 EP disclosed
EP-1305024-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC Alteon, Inc. (US) 2003-05-02 EP disclosed
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID SYNVISTA THERAPEUTICS, INC. 2002-11-28 US disclosed
US-20020160993-A1 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. 2002-10-31 US disclosed
WO-2002053158-A1 METHOD FOR TREATING GLAUCOMA IB ALTEON, INC. (US) 2002-07-11 WO disclosed
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC ALTEON, INC. 2002-06-06 US disclosed
WO-2002007725-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE MMP1, COL1A1, COL2A1 KMT2A 4599/4885HSP90AB1 132/4885POLB 2072/4885
US-20020160993-A1 Method for treating glaucoma IC CHAT, MYOC, GAP43 KMT2A 4535/4885HSP90AB1 1200/4885POLB 3857/4885
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC MMP1, COL1A1, COL2A1 KMT2A 4545/4885HSP90AB1 284/4885POLB 2130/4885
US-20090124673-A1 Method for treating diabetic nephropathy REN, SLC5A2, SLC5A1 KMT2A 4493/4885HSP90AB1 1317/4885POLB 3981/4885
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID MMP1, COL1A1, COL2A1 KMT2A 4326/4885HSP90AB1 248/4885POLB 1901/4885
US-20090124674-A1 Method for treating congestive heart failure TNNI3, TNNT2, FABP3 KMT2A 4520/4885HSP90AB1 100/4885POLB 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.